Open AccessThe Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines
Author(s) -
Yonghui Liu,
Zhaoyu Wang,
Yuding Fan,
Mingjing Li,
Haomiao Zhu,
Kun Wang,
Meng Meng,
Wei Zhao
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s273883
Subject(s) - adjuvant , immune system , immunogenicity , antigen , muc1 , immunotherapy , cancer immunotherapy , cancer vaccine , antibody , immunology , immunopotentiator , medicine , tumor antigen , cancer , cancer research
Therapeutic tumor vaccines are one of the most promising strategies and have attracted great attention in cancer treatment. However, most of them have shown unsatisfactory immunogenicity, there are still few available vaccines for clinical use. Therefore, there is an urgent demand to develop novel strategies to improve the immune efficacy of antitumor vaccines.